Predictive Biomarkers for Treatment With Amivantamab Plus Lazertinib Among EGFR-Mutated NSCLC in the Post-Osimertinib Setting: Analysis of Tissue IHC and ctDNA NGS

News
Video

Related Videos
Jean L. Koff, MD, MS
Rohan Garje, MD
Debu Tripathy, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Benjamin Garmezy, MD
Millie Das, MD
Jeffrey P. Townsend, PhD
Michael Iglesia, MD, PhD
Jean L. Koff, MD, MS
Related Content
Rebecca A. Dent, MD, MSc, of National Cancer Center Singapore and Duke-NUS Medical School

Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC

May 15th 2024
Article
Jubilee Brown, MD, professor, director, Gynecologic Oncology, Atrium Health Levine Cancer Institute

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

May 13th 2024
Podcast
FDA

FDA Grants Accelerated Approval to Liso-Cel for Relapsed/Refractory Follicular Lymphoma

May 15th 2024
Article
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, professor, division head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; codirector, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute

Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors

May 9th 2024
Podcast
Peter Schmid, MD, PhD, FRCP

Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC

May 15th 2024
Article
Samilia Obeng-Gyasi, MD, MPH

Lower Neighborhood Opportunity Is Linked With Increased Stress, Risk of All-Cause Mortality in Breast Cancer

May 15th 2024
Article